ALLOGENE THERAPEUTICS, INC. CAR T Together was created in response to several real-world access challenges that have emerged since the commercial introduction of autologous CAR T five years ago - chief among them, the supply bottleneck created given the complex, individualized manufacturing process inherent in their delivery. This inaugural group aims to support innovation and bring awareness to clinical trials that may ultimately lead to the availability of an allogeneic CAR T product for patients.
A new survey of
While the vast majority of late-stage cancer patients are eligible for CAR T treatment, only half of patients who are eligible for currently FDA approved autologous CAR T therapies receive treatment, according to the survey.1 Of those patients eligible for treatment, 12% were able to receive treatment within one month, with approximately 40% waiting three to six months or longer to receive treatment as their disease worsens.1
To improve access bottlenecks, CAR T Together brings together oncologists from preeminent research institutions nationwide who want to inspire collaboration to move cancer treatment options forward, supporting the advancement of science, the development of next-generation therapies and addressing the limitations of current therapies.
'Many of the physicians who are part of CAR T Together here and behind the scenes were critical in advancing autologous CAR T therapies. These first-generation CAR Ts transformed how we treat certain difficult-to-treat cancers, but the arduous, individualized manufacturing process and complex supply chain have made it hard for drugmakers to keep up with growing demand,' said
Equal parts collaboration, innovation and compassion, CAR T Together harnesses the spirit of cooperation needed to bring about the next cell therapy revolution and will collaborate with investigators and institutions in an effort to expedite clinical trial enrollment. The inaugural CAR T Together participants include:
'The best treatment is the one patients can get. These findings show us that unfortunately, one of the greatest barriers for patients is access to innovation,' said
Survey Findings
Extensive wait times for FDA-approved CAR T have become increasingly common and resulted in many physicians making hard decisions - which of their eligible patients will get a scarce manufacturing slot versus who will need to go on a waiting list as their disease continues to progress. A new in-depth survey of 50 U.S.-based hematologist-oncologists, physician assistants, nurse practitioners, and registered nurses from academic centers with CAR T therapy capabilities sheds new light on the evolving landscape and underscores the growing unmet need.
The survey results revealed
Only half of late-stage cancer patients who are eligible for currently FDA approved autologous CAR T therapies receive treatment.
While 82% of respondents agree that CAR T therapies have changed how they manage aggressive cancers, extensive wait times and manufacturing limitations keep many eligible patients from receiving treatment.
Of those patients eligible for treatment, only 12% are able to receive treatment within one month, with approximately 40% waiting up to six months or longer to receive treatment as their disease worsens.
For eligible patients, disease progression, manufacturing capacity and comorbidities were the top barriers.
Increased patient demand, manufacturing capacity and time to treatment are cited by respondents as the three biggest challenges facing CAR T adoption in the future.
The survey was sponsored by
About CAR T Together
CAR T Together is a first-of-its-kind initiative that brings together oncologists from preeminent research institutions to harness the spirit of cooperation needed to make the next revolution for cell therapy a reality - potentially turning the promise of scalable, off-the-shelf (allogeneic) CAR T products into a reality and expanding access to cancer patients.
About
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: expectations regarding the future demand for CAR T products and the supply of autologous CAR T products; the ability to develop allogeneic CAR T products; the ability to enroll patients in clinical trials of allogeneic CAR T products; the results from the survey, which may not be representative of all CAR T treatment providers and may change as the treatment landscape evolves and the potential benefits of allogeneic CAR T. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the
Contact:
Tel: (714) 552-0326
Email: Christine.Cassiano@allogene.com
(C) 2022 Electronic News Publishing, source
